Kornimate/medical-research-clean huggingface dataset:
hfnc for induction during bariatric surgery patients.

Conditions: Lung Collapse

Summary: this study aims to compared the effects of high flow nasal during the induction and during the weaning of anesthesia on intraoperative and postoperative oxygenation and postoperative atelectasis in obese patients undergoing bariatric surgery versus the standard of care, which consists in supplemental oxygen with face mask (venturi mask).


Eligibility criteria:
inclusion criteria: * body mass index \> 35 kg/m2 * bariatric surgery * informed consent signed exclusion criteria: * age \ 80yr * pregnancy or breast-feeding status * patients with previous known respiratory disease * hemodynamic instability at entry (need of vasopressors or ionotropes at entry or a ventricular assist device
covid-19 resource offers among rent and utility assistance applicants in st. louis

Conditions: Behavior and Behavior Mechanisms; Communication

Summary: the purpose of this study is to evaluate health messaging strategies that help individuals with a high degree of housing-related needs engage in covid-19 vaccination and testing behaviors. findings from this research can help other communities determine how best to integrate social needs and covid-19 prevention services. participants' contact information will be shared with us by 211 with the participants' previously given consent. the study team will send via text message a link to a survey that includes a screen where they will provide informed consent. those who provide consent will be randomly assigned to receive one of two surveys. the order of the offers is what varies across the surveys. participants will be asked, along with other survey items, if they have been vaccinated against covid-19. if they have not, they will be asked if they are interested in receiving help to receive a vaccine. participants will also be asked if they are interested in receiving an at-home covid self-test. if they say yes to assistance with vaccination, a vaccine navigator will call and assist them. if they say yes to receiving a covid test, the study team will ship them a test that has been procured from the city of st. louis mayor's office. one month later participants will be sent a follow-up survey that asks about their experiences either with testing or with vaccination if applicable.


Eligibility criteria:
inclusion criteria: * applicants for rent and utility assistance in st. louis city or county * english language proficiency * be willing to be contacted via text message or email * resident of st. louis city or county exclusion criteria: * n/a
postoperative pain and discomfort after orbital decompression

Conditions: Surgery; Anesthesia; Pain

Summary: the purpose of this study is to evaluate the postoperative pain and discomfort using flurbiprofen axetil or nalbuphine administration after orbital decompression under general anesthesia.

to investigate postoperative analgesia achieved with intraoperative administration of intravenous nalbuphine and flurbiprofen axetil in patients undergoing orbital decompression

Eligibility criteria:
inclusion criteria: * 16-75 years old * diagnosed as thyroid eye disease * bone removal orbital decompression under general anesthesia * american society of anesthesiologists (asa) physical status of i-ii exclusion criteria: * body mass index (bmi) \ 35 * any uncontrolled clinical problems

Keywords: postoperative pain general anesthesia postoperative discomfort
continuing care following drug abuse treatment: linkage with primary care

Conditions: Substance Abuse; Substance Dependence; Substance, Addiction; Alcohol Abuse

Summary: this component of a larger center of research excellence grant improves treatment for drug abuse by developing effective linkages between specialty drug treatment and primary health care.

this is a longitudinal two-arm quasi-experimental 3-month alternating off/on design over a 30 month period in which, after a random start, the linkage condition alternately is added to usual care in the chemical dependency (cd) clinic and then removed. we compare usual care to usual care plus linkage. follow-up interviews will be conducted at 6, 12 and 24 months. the linkage intervention includes usual care plus 1) sessions on activation regarding overall health behaviors and on selecting a primary care physician and communicating with him/her, and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and primary care physician. the intervention aims to place drug abuse problems in the context of overall health and health care and to activate patients to increase involvement in their own health care.

Eligibility criteria:
inclusion criteria: * research participants will be adult patients at the kaiser permanente san francisco chemical dependency recovery program, who have completed 2 weeks of treatment. exclusion criteria: * patients with a diagnosis of dementia, mental retardation, or who are actively psychotic or suicidal will be excluded by their clinician.

Keywords: substance abuse substance dependence substance, addiction alcohol abuse prevention and control preventative health services patient centered care
use of the modified puqe score on admitted cases of hyperemesis gravidarum (hg) to guide response to treatment

Conditions: Hyperemesis Gravidarum

Summary: use of the puqe score to judge the need for admission in cases of hyperemesis gravidarum evaluation of the response to treatment by the puqe score

nausea and nomiting of pregnancy (nvp) affects up to 80% of pregnant women . severe nvp is one of the most common indications for hospital admission among pregnant women, with typical stays of between 3 and 4 days . onset of nvp is in the first trimester. it typically starts between the fourth and seventh weeks of gestation, peaks in approximately the ninth week and resolves by the 20th week in 90% of women. if the initial onset is after 10+6 weeks of gestation, other causes need to be considered there is a broad spectrum of nausea and vomiting of pregnancy (nvp) severity, ranging from mild, occasional nausea to severe, intractable vomiting requiring hospitalisation (hyperemesis gravidarum). hyperemesis gravidarum(hg) is defined severe, protracted nausea and vomiting associated with weight loss of more than 5% of prepregnancy weight, dehydration and electrolyte imbalances. the exact underlying pathophysiology is unknown, but etiology is believed to be multifactorial, including endocrine, gastrointestinal and environmental factors.5 risk factors include lower maternal age, primigravidity, lower socioeconomic background and non-smoking status. admission for hyperemesis gravidarum depends on clinical impression by the attending or referring physician. there is a need for classification the severity of nvp to restrict admission to those who need admission. an objective and validated index of nausea and vomiting such as the pregnancy-unique quantification of emesis (puqe) score may be used for this purpose. this questionnaire contains three questions regarding the time-span of nausea, vomiting and retching respectively, as well as one question assessing the global psychological and physical quality of life (qol). initially the questionnaire evaluated symptoms during last 12 hours, but it has been modified to encompass 24 hours as well as the whole of first trimester of pregnancy the puqe questionnaire was used in several studies to assess the effect of antiemetic treatments for emesis and hyperemesis . in this study, the role of puqe in evaluating need for inpatient admission will be studied. also, the response to treatment inside the hospital will be assessed

Eligibility criteria:
inclusion criteria: * women hospitalized due to hyperemesis gravidarum with at least two out of three criteria; dehydration, weight loss \> 5% of prepregnancy weight (if known) or electrolyte imbalance/ketonuria. * gestational age between 6_16 weeks. exclusion criteria: 1. women suffered from other diseases causing nausea and vomiting : * gastritis * renal diseases * hepatic disorders * throid disorders 2. the gestational length was more than 16 weeks at inclusion.

Keywords: puqe score
antithrombotic activities of a novel yogurt drink

Conditions: Cardiovascular Diseases

Summary: this study aims to evaluate antithrombotic activities of novel yoghurt drink in healthy adult volunteers

this randomized controlled, double-blinded crossover study aims to investigate the antithrombotic activities of a novel yoghurt drink in healthy adult volunteers. it is anticipated that the novel drink containing beneficial polar lipids will reduce platelet aggregation in participants and consequently decrease the onset of cardiovascular disease. in phase i, the subjects will provide blood samples after overnight fasting and then take either a yoghurt drink (yd) or placebo (that does not contain polar lipids) daily for 4 weeks. following this period, they will again provide blood samples. then, after a 2-week washout period in which the subjects do not take any yoghurt or placebo drink , phase ii of the clinical trial will commence. this is the crossover phase in which subjects who took yd will now be given a placebo drink, and vice versa, over 4 weeks. a total of 80 blood samples will be collected for analysis.

Eligibility criteria:
inclusion criteria: * healthy adults exclusion criteria: * volunteers need to be off medication and off any dietary supplements. * subjects must not have any blood clotting disorders or dyslipidaemia. * dairy intake needs to be within a normal range of 1-2 portions a week. * unwilling to follow the study requirements.
evaluation of patients with idiopathic pulmonary fibrosis (ipf) through an ipf registry

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.


Eligibility criteria:
inclusion criteria 1. male or female greater or equal to age 18. 2. referral by physician with the diagnosis of ipf, or interstitial lung disease (ipf considered likely). exclusion criteria (a) unwilling or unable to give written informed consent.
topical antifungal treatment for tinea pedis

Conditions: Tinea Pedis

Summary: the purpose of this study is to determine if a topical antifungal cream is safe and effective for the treatment of tinea pedis.


Eligibility criteria:
inclusion criteria: * moderate erythema, moderate scaling, and mild pruritus exclusion criteria: * pregnancy and allergies

Keywords: tinea pedis antifungal
a rollover protocol of elacestrant, in combination with onapristone, for patients with er+, pr+, her2- advanced or metastatic breast cancer

Conditions: Breast Cancer

Summary: this is a rollover study for patients enrolled in the discontinued elona clinical trial (ona-xr-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.


Eligibility criteria:
inclusion criteria: * patient is currently enrolled in the elona clinical study (ona-xr-103) and receiving onapristone or elacestrant, either alone or in combination. * patient is currently benefiting from the treatment in the elona clinical study, as determined by the investigator. * patient currently has no evidence of progressive disease, as determined by the investigator. exclusion criteria: * pregnant or nursing (lactating) women. * female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception, throughout the study and for up to 30 days after stopping study treatment.
catheter ablation versus antiarrhythmic drugs for outflow tract ventricular arrhythmias

Conditions: Ventricular Tachycardia; Ventricular Premature Complexes

Summary: a randomized, parallel, open study comparing catheter ablation versus antiarrhythmic drugs for outflow tract ventricular arrhythmias


Eligibility criteria:
inclusion criteria: 1. presence of ventricular ectopic beats (veb) with left-bundle-branch block morphology or right-bundle-branch block morphology and positive concordance throughout the chest leads, inferior axis and at least one of the following: 1. \>2000 isolated veb/24h 2. symptomatic monomorphic ventricular tachycardia 3. left ventricular disfunction supposed to be due to tachycardia-induced cardiomyopathy exclusion criteria: 1. known structural heart disease 2. pregnancy 3. life expectancy \< 1 year
prospective observational study of pravafenix cap

Conditions: Dyslipidemias

Summary: to observe the effiacay, safety and risk of developing diabetes, review the patients chars who had administrated or neet to administrate the pravafenix cap for enroll period, it is an prospective observational study that only collect the collectable information follwoing the hospital visiting date from enroll point to information collecting date. there is no extra visit for this study. observe the data which has been collected for 3 yearts every year from enroll point, if the patients agree to be participated in this study and are suitable in inclusion/exclusion criteria. if the lipid-lowering drugs(only ezetimibe is possible) is add-on the pravafenix cap administrating period, it will be analyzed by laering analysis separately. but, the reason why it is add-on to have to be written on e-crf.


Eligibility criteria:
inclusion criteria: among the patients with artheriosclerotic cardiovascular heart failure who have been hopitalized or visited the hospital. 1. men or women over 20 years old 2. patients who had already administrated or need to administrate the pravafenix cap 3. patients who have abnormal opinion(dyslipidemia) about ldl-c, tg, hdl-c at the enroll point * 70mg/dl ≤ ldl-c ≤ 160mg/dl * 150mg/dl ≤ tg ≤ 500mg/dl or hdl-c \< 40mg/dl(men), 50mg/dl(women) 4. voluntary written informed consent to study participation exclusion criteria: 1. patient who have hypersensitivity about pravafenix cap or ingredients of the pravafenix cap. 2. patients suffer from liver disease (biliary cirrhosis, activated hepatophay or lasting potentiation of the transaminase 3 times excess from normal valus(which has no cause). 3. patients suffer from kidney disease(ccr \< 60ml/min) 4. patients have photo-allergy (allergic reaction causeed by sunlight or exposure to uv light) or phototoxic reactions (damage to skin caused by exposure to sunlight or uv light) during treatment with fibrates(lipid-modifying medicines) or ketoprofen (an anti-inflammatory medicine that can be used orally or on the skin for muscle and bone disorders, and orally for gout or period pain). 5. acute or chronic patients who have high triglycerides academia. 6. pregnant or breat-feeding 7. someone who have a history of muscle problems during treatment with cholesterol-controlling medicines called 'statins' (such as simvastatin, atorvastatin, pravastatin or rosuvastatin) or fibrates (such as fenofibrate and bezafibrate). 8. pateints who have uncontrolled hypothyroidism or hyperthyroidism. 9. patinets who couldn't be participated in the study by the other opinion of the investigator.
efficacy and safety of tc cream in treating patients with psoriasis vulgaris

Conditions: Psoriasis Vulgaris

Summary: a double-blind, randomized, placebo-controlled, parallel-controlled, two-center, phase iib clinical trial to evaluate the efficacy and safety of tc cream in treating patients with psoriasis vulgaris


Eligibility criteria:
inclusion criteria: * age of 18-70 years old. both men and women and members of all races and ethnic groups * consistent with diagnostic criteria of stable phase psoriasis vulgaris and have at least two target lesions suitable for evaluation * women of childbearing age must be using birth control strategies defined by one of the following: 1) a barrier method (condom) and/or 2) oral contraceptives, during the 8-week study period. * isga score ≥ 2 (at least mild severity) * bsa (stable stage group): 1%≤ to ≤20% * signed a written informed consent document * no additional exposure to the sun exclusion criteria: * subjects in pregnancy, preparing for pregnancy or breast feeding * history of hyperergic or photosensitivity * history of complicated cardiovascular diseases, cerebrovascular diseases, severe primary diseases of hepatic, kidney and hematopoietic system, or patients with psychiatric disorders * history of photosensitive diseases such as porphyria, chronic actinic dermatitis, xeroderma pigmentosa * within 4 weeks prior to randomizations, patients have taken treatment with following approved or investigational psoriasis therapies on the target lesions: * topical treatments * puva, uvb or grenz ray therapy. * any systemic treatments other than biologicals with a possible effect on psoriasis (e.g., corticosteroids, vitamin d analogues, hydroxycarbamide, azathioprine, methotrexate, cyclosporine, other immunosuppressant). * any types of other investigational therapies for psoriasis * within 3 months prior to randomizations, patients have taken systemic treatments with retinoids or biological therapies (marketed or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab). * planned initiation of, or changes to, concomitant medications that could affect psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the study. * history of allergic reactions attributed to compounds of similar chemical or biologic compositions to coumarins.
12 week study of anti-viral effect of oral ut-231b in non-cirrhotic hepatitis c patients who have failed interferon-based therapy.

Conditions: Hepatitis C

Summary: this is a multi-center study. neither the study subjects nor the physicians will know what treatment an individual subject is receiving. subjects will be randomly assigned (like flipping a coin) to one of five treatment groups. the treatment groups include four different dosing groups of active study drug and one group of subjects who will receive placebo. a 12 week follow up period occurs after the 12 weeks of dosing. the study endpoint is a reduction in hepatitis c viral load.


Eligibility criteria:
inclusion criteria: * patients must be adults, * have a positive hepatitis c antibody test, * and be genotype 1, with a minimum of 100,000 iu of hepatitis c virus by nucleic acid testing, be non-cirrhotic with a metavir score of f0-3 (or equivalent) on liver biopsy, and have failed previous therapy with interferon or peg interferon monotherapy, interferon plus ribavirin, or peg interferon and ribavirin. exclusion criteria: * diabetics are excluded.

Keywords: hepatitis c
dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia in japan

Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelogenous Leukemia, Chronic, Chronic Phase

Summary: the purpose of this study is to evaluate effectiveness of dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in japan.


Eligibility criteria:
inclusion criteria: * newly diagnosed chronic myeloid leukemia in the chronic phase * 20 years old over * ecog performance status (ps) score 0-2 * adequate organ function (hepatic, renal and lung) * signed written informed consent exclusion criteria: * a case with the double cancer of the activity * women who are pregnant or breastfeeding * the case of pleural effusion clearly * patients with complications or a history of severe or uncontrolled cardiovascular failure following * have a myocardial infarction whithin 6 months * have an angina within 3 months * have a congestive heart failure within 3 months * have a qtc interval of more than 450msec at baseline * a serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy

Keywords: chronic myelogenous leukemia chronic phase phase ii dasatinib
exploring proqol, health status, job involvement and turnover in medical professionals

Conditions: Intention to Stay, Turnover Behavior

Summary: the study design is a cross-sectional study. purposive sampling will be conducted in three hospitals in the central of taiwan. the participants will include physicians, nurse practitioners and nurses. the number of 550 participants will be recruited. the measurements are questionnaires include demographic data, professional quality of life scale (proqol), job involvement questionnaire (jiq), sf-36 and intention to stay questionnaire.

medical and nursing care is a high-pressure work environment. the charterer of medical and nursing care includes urgency of patients' problems, an unpredictable number of patients, and lack of medical professionals. this high-level of pressure working environment not only affects the persons' physical and mental health, increase turnover rate, but also might indirectly reduce the quality of care, even threaten the life of patients. the purpose of this study is to explore the correlation between professional quality of life, health status, job involvement and intention to stay in medical professionals, and the predictive factors of intention to stay and turnover behavior. the study design is a cross-sectional study. purposive sampling will be conducted in three hospitals in the central of taiwan. the participants will include physicians, nurse practitioners, and nurses. the number of 550 participants will be recruited. the measurements are questionnaires include demographic data, professional quality of life scale (proqol), job involvement questionnaire (jiq), sf-36 and intention to stay questionnaire.

Eligibility criteria:
inclusion criteria: 1. aged over 20 years old 2. currently serving as a hospital care provider 3. job title as attending physician, resident, nurse practitioners, nurse 4. directly practicing in patients' care exclusion criteria: 1. medical director 2. clinical researcher

Keywords: professional quality of life, medical professionals, job involvement, intention to stay,
clinical performance of bioactive highly filled injectable flowable composite for direct posterior occlusal conservative restorations using fdi criteria: two year randomized clinical trial

Conditions: Dental Caries

Summary: the aim of this study is to evaluate clinical performance of bioactive highly filled injectable flowable composite for direct posterior occlusal conservative restorations using fdi criteria


Eligibility criteria:
inclusion criteria:the inclusion criteria: patient age range from 16-45 years, with a premolar indicated for extraction, patients required at least a couple of class i restorations. the patient should have good general health. - exclusion criteria:where the exclusion criteria will be: poor oral hygiene, sever or chronic periodontal disease or bruxism, severe tooth sensitivity, non-vital or fracture or cracked teeth, defective restorations or bleaching procedures during the last 6 months, pregnancy, and/or lactation, and allergy to the main components of the products to be used in the study. -